This research demonstrates increased antibody levels in ATTR cardiomyopathy, suggesting a new immune mechanism in its treatment.
Naturally-occurring TTR-targeting antibodies are present from birth, modulated by disease and therapy, and inhibit fibril formation. These findings reveal an unrecognized immune mechanism with potential relevance for ATTR-CM pathogenesis and treatment.
No takes yet. Share an insight, caveat, or question.
Settelmeier et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: